-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3041 Treatment Outcomes for Patients with TP53-Mutated Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Indolent lymphoma, Aggressive lymphoma, Lymphoid Malignancies
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Na Zhang, Master of Medicine1*, Jiegang Xu2*, Chengxin Luo2*, Dongfeng Zeng1*, Shuangnian Xu2* and Xi Li1*

1Department of Hematology, Daping Hospital, Third Military Medical University (Army Medical University), Chongqing, China, Chongqing, China
2Department of Hematology, Southwest Hospital, Third Military Medical University,(Army Medical University), Chongqing, China, Chongqing, China

Abstract

Background TP53 mutation, which is present in 10% to 20% of patients with mantle cell lymphoma (MCL), is the most poor predictor of early disease progression and death for MCL patients. Many clinical trials have been conducted to improve the therapeutic efficacy for these patients, but the best available treatment is still unknown. Thus, we conducted a systematic review and meta-analysis to evaluate the outcome of current various treatments for TP53-mutated (TP53m) MCL.

Methods EMBASE and MEDLINE were searched from inception to December 29, 2023 without language restriction. Randomized controlled trials, single-arm trials, prospective observational studies, and retrospective studies which reported the treatment outcomes for newly diagnosed or relapsed/refractory TP53m MCL patients were included. Outcomes included complete remission (CR) rate, overall response (OR) rate and overall survival (OS).

Results A total of 28 studies which met the inclusion criteria were included in this systematic review and meta-analysis. The treatment approaches for TP53m MCL patients in the included studies contained targeted therapy, targeted therapy combined chemotherapy, hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy. The CR rate and OR rate for TP53m MCL patients with the current treatment was 68% (95%CI 57%-79%, I2=41%) and 79% (95%CI 65%-90%, I2=71%) respectively. For newly diagnosed TP53m MCL patients, targeted therapy was reported to be with the highest CR rate of 79% (95%CI 62%-93%, I2=3%) and the highest OR rate of 96% (95%CI 82%-100%, I2=10%). For relapsed/refractory TP53m patients, CAR-T therapy showed the highest CR rate of 84% (95%CI 64%-98%, I2=43%) and the highest OR rate of 95% (95%CI 73%-100%, I2=62%). The 1-year OS rate and 2-year OS rate for TP53m MCL patients with the current treatment was 63% (95%CI 52%-73%, I2=20%) and 53% (95%CI 38%-69%, I2=44%) respectively. For newly diagnosed TP53m MCL patients, 1-year OS rate and 2-year OS rate for allo-HSCT was 69% (95%CI 50%-83%, I2=54%) and 62% (95%CI 45%-77%, I2=0%), respectively. For relapsed/refractory TP53m MCL patients, 1-year OS rate was 43% (95%CI 10%-82%) for targeted therapy, 61% (95%CI 47%-73%) for CAR-T therapy, and 2-year OS rate was 44% (95%CI 32%-58%) for CAR-T therapy.

Conclusions Although targeted therapy or CAR-T therapy can achieve an relatively high response rate for newly diagnosed or relapsed/refractory TP53m MCL patients, survival was still poor for these patients and more effective treatment strategies need to be exploded.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH